Al-Mehisen R, Al-Mohaissen M, Yousef H. Cardiac involvement in disseminated diffuse large B-cell lymphoma, successful management with chemotherapy dose reduction guided by cardiac imaging: A case report and review of literature. World J Clin Cases 2019; 7(2): 191-202 [PMID: 30705895 DOI: 10.12998/wjcc.v7.i2.191]
Corresponding Author of This Article
Maha Al-Mohaissen, MBBS, SBIM, ArBIM, MRCP, Associate Professor, Department of Clinical Sciences (Cardiology), Princess Nourah Bint Abdulrahman University Research Chair in Cardiovascular Disease in Women, Princess Nourah Bint Abdulrahman University, PO Box 40847, Riyadh 11511, Saudi Arabia. mahaabdulrahman@hotmail.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 26, 2019; 7(2): 191-202 Published online Jan 26, 2019. doi: 10.12998/wjcc.v7.i2.191
Cardiac involvement in disseminated diffuse large B-cell lymphoma, successful management with chemotherapy dose reduction guided by cardiac imaging: A case report and review of literature
Rabah Al-Mehisen, Maha Al-Mohaissen, Hisham Yousef
Rabah Al-Mehisen, Department of Cardiology, Security Forces Hospital, Riyadh 11481, Saudi Arabia
Maha Al-Mohaissen, Department of Clinical Sciences (Cardiology), Princess Nourah Bint Abdulrahman University Research Chair in Cardiovascular Disease in Women, Princess Nourah Bint Abdulrahman University, Riyadh 11511, Saudi Arabia
Hisham Yousef, Department of Internal Medicine, Division of Hematology/Oncology, Security Forces Hospital, Riyadh 11481, Saudi Arabia
Author contributions: Al-Mohaissen M and Al-Mehisen R designed the report; Al-Mehisen R and Yousef H collected the patient’s clinical data; Al-Mehisen R, A-Mohaissen M and Yousef H analyzed the data and wrote the paper.
Informed consent statement: Consent was obtained from the patient for publication of this report and any accompanying images and is available upon request.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The CARE checklist has been filled and submitted before and is not among the resubmission requirements at the journal website.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Maha Al-Mohaissen, MBBS, SBIM, ArBIM, MRCP, Associate Professor, Department of Clinical Sciences (Cardiology), Princess Nourah Bint Abdulrahman University Research Chair in Cardiovascular Disease in Women, Princess Nourah Bint Abdulrahman University, PO Box 40847, Riyadh 11511, Saudi Arabia. mahaabdulrahman@hotmail.com
Telephone: +966-11-8238882
Received: October 15, 2018 Peer-review started: October 15, 2018 First decision: December 9, 2018 Revised: December 26, 2018 Accepted: January 3, 2019 Article in press: January 4, 2019 Published online: January 26, 2019 Processing time: 104 Days and 23.9 Hours
Core Tip
Core tip: Few Clinicians are comfortable managing a patient with extensive cardiac involvement by lymphoma, due to the limited clinical experience and paucity of data on such cases. Despite the heterogeneity in management, early diagnosis and treatment may lead to remission. Decisions on management should be individualized due to the variability in the pattern and magnitude of cardiac disease. In cases with extensive involvement, reducing the chemotherapy dose with dose escalation to therapeutic levels may be safe and effective management approach. Improvements in imaging technology will likely increase the rate of pre-mortem detection of cardiac lymphoma leading to better understanding of this highly fatal condition and improved patient survival.
